Eligibility criteria
AVMA incentives are intended for vaccines manufactured in Africa. The Gavi Board approved a set of “AVMA terms”, which define the key elements of AVMA including the eligibility criteria a vaccine must meet to qualify for AVMA incentives. Please see AVMA Guidance for Manufacturers for more details.
Priorities
All vaccines included in Gavi’s portfolio are eligible for Accelerator payments. AVMA Priority vaccines and all vaccines in Gavi’s portfolio that are produced on AVMA Priority technology platforms are also eligible for Milestone payments and Accelerator payments at a higher rate (see “Incentive values” tab above). These priorities have been defined to support the supply of vaccines that would be complementary to market health on a global level, or else have strategic importance for the African continent.
The AVMA Priority vaccines are:
- Oral cholera
- Malaria
- Measles-rubella
- Hexavalent (wP)
- Yellow fever
- Ebola (AVMA Priority only with the following required profile: indication against at least two Ebola species and improved thermostability as from -20°C)
- Rotavirus (AVMA Priority only with the following required profile: single-dose blow-fill-seal presentation)
- Pneumococcal (AVMA Priority only with the following required profile: minimum 13-valent)
More information on the priority vaccine markets can be found on the Vaccine Markets Dashboard.
The AVMA Priority technology platforms are:
Additional important details are provided in AVMA Guidance for Manufacturers.
Incentive values
AVMA has a tiered incentive structure, designed to align with AVMA’s objectives, with the following incentive values for Milestone and Accelerator payments (subject to caps (see Funding caps tab above):
Milestone payment
- US$ 25 million: any Gavi portfolio vaccine whose drug substance is manufactured in Africa on an AVMA Priority technology platform (i.e. mRNA or viral vector)
- US$ 20 million: AVMA Priority vaccines whose drug substance is manufactured in Africa
- US$ 10 million: AVMA Priority vaccines for which only ‘fill and finish’ takes place in Africa
Manufacturers may only receive a single Milestone payment per eligible vaccine. For instance, manufacturers performing both ‘drug substance’ and ‘fill-finish’ steps will only receive the ‘drug substance’ incentive payment (either “AVMA Priority platform drug substance” at US$ 25 million or “AVMA Priority vaccine on any other platform” at US$ 20 million).
Accelerator payment
- US$ 0.50 per dose: any Gavi portfolio vaccine whose drug substance is manufactured in Africa on an AVMA Priority technology platform (i.e. mRNA or viral vector)
- US$ 0.50 per dose: AVMA Priority vaccines whose drug substance is manufactured in Africa
- US$ 0.40 per dose: any other Gavi portfolio vaccine whose drug substance is manufactured in Africa
- US$ 0.30 per dose: any Gavi portfolio vaccine for which only ‘fill and finish’ takes place in Africa, up to a cap of US$ 1.00 per vial
Manufacturers may only receive the highest applicable Accelerator payment for each delivered eligible vaccine dose. For instance, manufacturers performing both ‘drug substance’ and ‘fill and finish’ steps will only receive the ‘drug substance’ incentive payment for each delivered dose (at either the US$ 0.50 or the US$ 0.40 rate).
Additional important details are provided in AVMA Guidance for Manufacturers.
Procurement pathway
As of the launch of AVMA, only vaccines that are procured via successful UNICEF tenders (and fulfil all other criteria) are eligible for Accelerator payments. The integration of a future pooled procurement mechanism established on the African continent could also be considered at a later stage, with the process and decision subject to determination in line with AVMA’s governance arrangements.
Additional important details are provided in AVMA Guidance for Manufacturers.
Funding caps
To ensure diversification of the funds disbursed by AVMA, a set of ‘caps’ has been established as part of AVMA’s design. The caps set the maximum amount that can be disbursed by AVMA per manufacturer, per vaccine category, as Milestone payments, and for all payments made in relation to ‘fill and finish-only vaccines’. These caps aim to ensure that AVMA funding mainly incentivises drug substance manufacturing, as well as a diversified manufacturer and vaccine/platform base across the continent. Milestone payments are capped to ensure sufficient funding is available to help manufacturers bring their product to market. Hence disbursement caps are set as follows:
- US$ 250 million per manufacturer (across Milestone and Accelerator payments cumulatively), of which US$ 50 million for ‘fill and finish-only vaccines’
- US$ 300 million per vaccine category/market
- US$ 250 million for total Milestone payments across the life of AVMA
- US$ 250 million for ‘fill and finish-only vaccines’
- The overall mechanism is capped at net funds raised for AVMA, deducting operational costs incurred.
Additional important details are provided in AVMA Guidance for Manufacturers.